NGEN (NervGen Pharma) Buyback Yield %: -3.74 (As of Jun. 30, 2026)


NGEN NervGen Pharma Corp NGEN
22 GF Score
Price $2.02
! 2 Warning Signs
View Full Analysis

What is NervGen Pharma Buyback Yield %?

NervGen Pharma NGEN +4.95% 22 Buyback Yield % is -3.74 as of Jun. 30, 2026. GuruFocus rates NGEN with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, NervGen Pharma ranks better than 63.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

NervGen Pharma's current buyback yield was -3.74%.

NervGen Pharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for NervGen Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma Buyback Yield % Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only -15.01 -20.80 0.00 -10.53 -2.74

NervGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.81 -1.11 -1.16 -2.78 -3.74

NGEN vs NKTX, UNCY, MDWD: Buyback Yield % Comparison

For the Biotechnology subindustry, NervGen Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NervGen Pharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Buyback Yield % falls into.


NGEN
22GF Score
NervGen Pharma Corp NGEN
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NervGen Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

NervGen Pharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 12.24) / 446.0344
=-2.74%

NervGen Pharma's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 12.2) / 305.10987
=-4.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -3.74 mean?
NervGen Pharma (NGEN) has a Buyback Yield % of -3.74 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NervGen Pharma and its competitors. According to the industry distribution chart, NervGen Pharma ranks #269 out of 742 companies in the Biotechnology industry, placing it in the top 36.3%.
Is NervGen Pharma's Buyback Yield % too high?
NervGen Pharma's current Buyback Yield % is -3.74. Based on the distribution chart, NervGen Pharma ranks #269 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NervGen Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does NervGen Pharma's Buyback Yield % compare to NKTX and UNCY?
According to the Biotechnology industry distribution chart, NervGen Pharma ranks #269 out of 742 companies for Buyback Yield %. This puts NervGen Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on NervGen Pharma and its competitors. NervGen Pharma's current Buyback Yield % is -3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NervGen Pharma stock overvalued right now?
NervGen Pharma (NGEN) has a current Buyback Yield % of -3.74. The current Buyback Yield % is -3.74. NervGen Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For NervGen Pharma (NGEN), the current Buyback Yield % is -3.74 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NervGen Pharma Business Description

Other Exchanges 9UA:Germany
Address 112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
22GF Score

Get the complete analysis for NGEN

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price